Social Media Ideas for Drug Development

<![CDATA[The Full Path of Drug Development, and Why So Few Drugs Make It: Q&A with Dr. Ying Huang]]>

UK oncology drug development analyzed over 25 years, with 2026 trial reboot

A new analysis published in British Journal of Cancer maps how oncology drug development in the UK has evolved over the past 25 years—and why the next phase needs a regulatory reth...

3 realms every drug development leader must bridge

Pharmaceutical research and development (R&D) has never lacked scientific ambition. The more challenging issue is transforming good science into programs that operate efficient...

Drug discovery Is changing. Drug development must change too.

In this New Scientist CoLab podcast, experts from global life sciences leader Cytiva explain the hidden, high-stakes science of purification that is required to close the gap betwe...

<![CDATA[Developing Better Drugs, Not Just More Drugs: Q&A with David Hung ]]>

<![CDATA[The Path from Discovery to Global Commercialization]]>

Mouse models and CRO selection critical to de-risking neurology drug development

CNS drug development lags far behind oncology, but translationally relevant mouse models can help close that gap and improve trial outcomes. The post Mouse models and CRO selection...

Top Preclinical CROs Bridging GLP and GCP for Seamless Drug Development

Key Takeaways Most drug development programmes hit a natural seam between preclinical and clinical work,... The post Top Preclinical CROs Bridging GLP and GCP for Seamless Drug Dev...

Peptris is using AI to find drug candidates to shorten the time it takes for laboratory validation

The Bengaluru-based company builds models that generate molecules and predict how they will behave, and has licensed its lead candidate to a US developer.

New Biotech-Academia Partnership Approaches to Empower the Drug Development Ecosystem

Addressing shifts in the global clinical development ecosystem and how academia and biotech can better partner to develop new therapies for patients.

Inaugural AACR D3 Opens With Insights From Leaders Across Drug Discovery and Development

During the opening session of the AACR Conference on Drug Discovery and Development, the conference cochairs—Patricia M. LoRusso, DO, PhD (hc), FAACR; Keith T. Flaherty MD, FAACR;...

<![CDATA[The Status of Nuvation Bio’s Pipeline]]>

<![CDATA[How Nuvation Bio Manages its Ongoing Clinical Trials]]>

Developing a Global Clinical Trial Strategy for Emerging Biotechs

Discussing how small biotechs can accelerate clinical development with fit-for-purpose global clinical trial strategies.

Exsure is working on a way to make chemotherapy less toxic, backed by peer-reviewed research

The Bhubaneswar biotech has built a patented drug-delivery platform aimed at cancer cells. It is in preclinical testing and raised Rs 3 crore, led by Unicorn India Ventures.

The Drug Changing Medicine

By EMANUEL SARKEES The United States is in the middle of what researchers are calling one of the most significant pharmacological developments in modern medicine. GLP-1 receptor ag...

<![CDATA[Why Biologics R&D Platforms Are Failing Complex Modalities and What Must Change]]>

Centrix and University of Sussex Collaborate to Drive Data-Driven Pharma Development

The KTP provides access to academic expertise while embedding that capability within Centrix’s business. This project represents an opportunity to apply advanced data science techn...

Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy

Aims to Raise Capital to Fund Global Clinical Studies for LNP7457 (PRMT5) & LNP8701 (SOS1)

How well are AI-discovered drugs faring in the clinic?

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.

‘A mouse can’t tell us what works’: UK scientists to grow miniature human organs for drug testing

Organoids and tissues grown from human cells promise more accurate results, with £20m Cambridge project to create standardised modelsMiniature human organs and other tissues are to...

Seamless Integration in Gene Therapy Process Development

A contract manufacturer running multiple adeno-associated virus (AAV) programs says early engagement between key stakeholders, proactive risk assessments and platform knowledge is...

From Cabozantinib to Zanzalintinib: Chemical Tweaks Open New Frontier in Product Hopping

For decades, the pharmaceutical industry’s most familiar strategy for extending the commercial life of a successful medicine has been to make a new version of it: a different formu...

AGC and Neusignal Therapeutics Collaborate on the Development of Alzheimer's Disease Drug Candidate “NTX-083”

AGC Inc. (Headquarters: Tokyo; President: Yoshinori Hirai; hereinafter “AGC”) highlights its end-to-end support capabilities as a small-molecule pharmaceutical CDMO as demonstrated...